86.64

1.23% 1.05

Arrowhead Pharmaceuticals Inc (ARWR)

Overview News Price History Option Chain Financials Why ARWR Down? Discussions Forecast Stock Split

Arrowhead Pharmaceuticals Inc stock is traded at $86.64, with a volume of 817.76K. It is up +1.23% in the last 24 hours and up +20.48% over the past month. Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.

Previous Close:

$85.59

Open:

$84.75

24h Volume:

817.76K

Relative Volume:

0.39

Market Cap:

$12.24B

Revenue:

$622.01M

Net Income/Loss:

$-271.86M

P/E Ratio:

-40.33

EPS:

-2.1484

Net Cash Flow:

$-45.87M

1W Performance:

-1.15%

1M Performance:

+20.48%

6M Performance:

+35.76%

1Y Performance:

+361.34%

1-Day Range:

$83.78

$87.17

1-Week Range:

$83.78

$90.97

52-Week Range:

$18.73

$95.49

Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile

Name

Arrowhead Pharmaceuticals Inc

Sector

Healthcare (1080)

Industry

Biotechnology (604)

Phone

626-696-4702

Address

177 E COLORADO BLVD, PASADENA, CA

Employee

711

Twitter

@ArrowheadPharma

Next Earnings Date

2026-08-04

Latest SEC Filings

ARWR's Discussions on Twitter

Compare ARWR vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ARWR Arrowhead Pharmaceuticals Inc	86.64	12.32B	622.01M	-271.86M	-45.87M	-2.1484
VRTX Vertex Pharmaceuticals Inc	505.75	133.25B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	803.48	82.16B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	851.29	54.80B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	203.71	43.99B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	347.48	40.62B	5.76B	514.49M	1.10B	4.4813

Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-21-26	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jun-05-24	Initiated	Goldman	Neutral
Dec-04-23	Initiated	BofA Securities	Buy
Sep-19-23	Initiated	Citigroup	Neutral
Jul-21-23	Initiated	TD Cowen	Outperform
May-12-23	Downgrade	SVB Securities	Outperform → Market Perform
Apr-26-23	Initiated	SMBC Nikko	Outperform
Apr-12-23	Upgrade	SVB Securities	Market Perform → Outperform
Mar-21-23	Initiated	Bernstein	Mkt Perform
Sep-09-22	Initiated	Morgan Stanley	Equal-Weight
May-11-22	Upgrade	Robert W. Baird	Neutral → Outperform
Jan-19-22	Resumed	Goldman	Buy
Aug-06-21	Reiterated	Chardan Capital Markets	Buy
Jun-04-21	Resumed	Robert W. Baird	Neutral
Feb-05-21	Reiterated	H.C. Wainwright	Buy
Dec-21-20	Downgrade	Robert W. Baird	Outperform → Neutral
Dec-16-20	Initiated	UBS	Buy
Nov-19-20	Initiated	Citigroup	Buy
May-13-20	Initiated	RBC Capital Mkts	Outperform
May-08-20	Upgrade	Oppenheimer	Perform → Outperform
Apr-15-20	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Mar-24-20	Upgrade	SVB Leerink	Underperform → Mkt Perform
Mar-17-20	Initiated	Goldman	Neutral
Jan-21-20	Initiated	SVB Leerink	Underperform
Dec-13-19	Initiated	Oppenheimer	Perform
Nov-29-19	Reiterated	Chardan Capital Markets	Buy
Nov-27-19	Reiterated	B. Riley FBR	Buy
Nov-25-19	Upgrade	Robert W. Baird	Neutral → Outperform
Oct-24-19	Downgrade	Robert W. Baird	Outperform → Neutral
Oct-22-19	Reiterated	Chardan Capital Markets	Buy
Oct-03-19	Initiated	Robert W. Baird	Outperform
Sep-07-18	Upgrade	B. Riley FBR	Neutral → Buy
Sep-06-18	Reiterated	Chardan Capital Markets	Buy
Aug-08-18	Reiterated	Cantor Fitzgerald	Overweight
Jul-02-18	Reiterated	Chardan Capital Markets	Buy

View All

Arrowhead Pharmaceuticals Inc Stock (ARWR) Latest News

Aug 14, 2026

Avoro Capital discloses 9.64% Arrowhead Pharmaceuticals (ARWR) stake including warrants - Stock Titan

Aug 14, 2026

Aug 12, 2026

Why Arrowhead Pharmaceuticals (ARWR) Is Back In The Spotlight - Sahm

Aug 12, 2026

Aug 11, 2026

Assenagon Asset Management S.A. Grows Stock Holdings in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat

Aug 11, 2026

Aug 10, 2026

How Investors Are Reacting To Arrowhead Pharmaceuticals (ARWR) Soaring Sales But Deepening Losses - simplywall.st

Aug 10, 2026

FY2026 Earnings Estimate for ARWR Issued By HC Wainwright - MarketBeat

Aug 10, 2026

Zacks Research Analysts Increase Earnings Estimates for ARWR - MarketBeat

Aug 10, 2026

Aug 09, 2026

Pacer Advisors Inc. Invests $1.50 Million in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat

Aug 09, 2026

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat

Aug 09, 2026

Aug 06, 2026

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Expected to Rise, HC Wainwright Analyst Says - marketbeat.com

Aug 06, 2026

Morgan Stanley Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $120 - Moomoo

Aug 06, 2026

Aug 05, 2026

Arrowhead Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $110.2, Implies 23% Upside - TradingView

Aug 05, 2026

Arrowhead buys PRV for $215M; Twist hopes to raise $300M in public offering - Endpoints News

Aug 05, 2026